Pear Therapeutics will solely be responsible for commercialization of its prescription digital therapeutics (PDTs)- reSET and reSET-O- therapies to treat substance use disorder (SUD) and opioid use disorder (OUD) respectivelyIn Apr’2018- the companies collaborated to develop and commercialize PDTs. The termination of prescription app deal is a part of Sandoz transformation and subsequent leadership change resulted in a reinforced focus on and capital allocation for Sandoz’s core businessSandoz will continue to partner with Pear and support the commercial efforts through a transition period to ensure patients access to reSET and reSET-O. reSET is a 90-days PDT intended to provide CBT while reSET-O is an 84-days PDT intended to increase retention of patients in outpatient treatment by CBT
Click here to read full press release/ article | Ref: Sandoz| Image: Pear Therapeutics
